Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Provided By GlobeNewswire
Last update: Jul 16, 2024
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -
- $26.5 Million Upfront Plus Up to $5.0 Million Milestone -
